Polynovo

Polynovo FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Polynovo (PNV.AX) as of Oct 28, 2026 is 128.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -81.60 % — a change of -257.73% (higher).

FCF Conversion

128.72 %

YoY

-257.73%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Polynovo is 2026 128.72 % . FCF Conversion Rate (FCF/EBITDA) of Polynovo was 2025 -81.60 % . It decreases by -257.73% higher compared to the previous year.

The Polynovo FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
310.03 AUD
Jan 1, 2020
221.07 AUD
Jan 1, 2021
82.90 AUD
Jan 1, 2022
213.63 AUD
Jan 1, 2023
151.50 AUD
Jan 1, 2024
14.94 AUD
Jan 1, 2025
-81.60 AUD
Jan 1, 2026
128.72 AUD
The Polynovo FCF Conversion history
YEARFCF ConversionYoY
128.72 %-257.73%
-81.60 %-646.20%
14.94 %-90.14%
151.50 %-29.08%
213.63 %+157.70%
82.90 %-62.50%
221.07 %-28.69%
310.03 %+160.94%
118.81 %+3.56%
114.73 %-6.60%
122.83 %-44.56%
221.56 %+141.90%
91.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polynovo Stock analysis

What does Polynovo do? Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polynovo stock

FCF Conversion Rate (FCF/EBITDA) of Polynovo is 128.72 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Polynovo changed from -81.60 % to 128.72 %, representing a -257.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Polynovo since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Polynovo with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Polynovo

All Key Metrics — Polynovo